161 related articles for article (PubMed ID: 1759815)
21. In-vitro activity of lytic peptides, inhibitors of ion transport systems and ionophorous antibiotics against Pneumocystis carinii.
Cirioni O; Giacometti A; Barchiesi F; Scalise G
J Antimicrob Chemother; 1998 Aug; 42(2):141-5. PubMed ID: 9738830
[TBL] [Abstract][Full Text] [Related]
22. Antimicrobial susceptibility of Pneumocystis carinii in culture.
Bartlett MS; Eichholtz R; Smith JW
Diagn Microbiol Infect Dis; 1985 Sep; 3(5):381-7. PubMed ID: 3875445
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of a hydroxynaphthoquinone, 566C80, in experimental Pneumocystis carinii pneumonitis.
Hughes WT; Gray VL; Gutteridge WE; Latter VS; Pudney M
Antimicrob Agents Chemother; 1990 Feb; 34(2):225-8. PubMed ID: 2327770
[TBL] [Abstract][Full Text] [Related]
24. Uptake and metabolism of L-serine by Pneumocystis carinii carinii.
Florin-Christensen M; Florin-Christensen J; Kaneshiro ES
J Eukaryot Microbiol; 1995; 42(6):669-75. PubMed ID: 8520579
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and antiparasitic and antitumor activity of 2, 4-diamino-6-(arylmethyl)-5,6,7,8-tetrahydroquinazoline analogues of piritrexim.
Rosowsky A; Papoulis AT; Forsch RA; Queener SF
J Med Chem; 1999 Mar; 42(6):1007-17. PubMed ID: 10090784
[TBL] [Abstract][Full Text] [Related]
26. In-vitro activity of atovaquone, sulphamethoxazole and dapsone alone and combined with inhibitors of dihydrofolate reductase and macrolides against Pneumocystis carinii.
Cirioni O; Giacometti A; Scalise G
J Antimicrob Chemother; 1997 Jan; 39(1):45-51. PubMed ID: 9044027
[TBL] [Abstract][Full Text] [Related]
27. 6,7-disubstituted 2,4-diaminopteridines: novel inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
Jackson HC; Biggadike K; McKilligin E; Kinsman OS; Queener SF; Lane A; Smith JE
Antimicrob Agents Chemother; 1996 Jun; 40(6):1371-5. PubMed ID: 8726003
[TBL] [Abstract][Full Text] [Related]
28. Extent of fungal contamination in rat-derived Pneumocystis carinii extracts and the effect on uptake of para-aminobenzoic acid.
Chung V; Shah K
J Eukaryot Microbiol; 1994; 41(5):80S-81S. PubMed ID: 7804277
[No Abstract] [Full Text] [Related]
29. Method of testing the susceptibility of Pneumocystis carinii to antimicrobial agents in vitro.
Cushion MT; Stanforth D; Linke MJ; Walzer PD
Antimicrob Agents Chemother; 1985 Dec; 28(6):796-801. PubMed ID: 3936409
[TBL] [Abstract][Full Text] [Related]
30. Activity of terbinafine against Pneumocystis carinii in vitro and its efficacy in the treatment of experimental pneumonia.
Contini C; Manganaro M; Romani R; Tzantzoglou S; Poggesi I; Vullo V; Delia S; De Simone C
J Antimicrob Chemother; 1994 Nov; 34(5):727-35. PubMed ID: 7706168
[TBL] [Abstract][Full Text] [Related]
31. Free and total para-aminobenzoic acid analysis in plants with high-performance liquid chromatography/tandem mass spectrometry.
Zhang GF; Mortier KA; Storozhenko S; Van De Steene J; Van Der Straeten D; Lambert WE
Rapid Commun Mass Spectrom; 2005; 19(8):963-9. PubMed ID: 15759312
[TBL] [Abstract][Full Text] [Related]
32. In-vitro activity of lytic peptides alone and in combination with macrolides and inhibitors of dihydrofolate reductase against Pneumocystis carinii.
Cirioni O; Giacometti A; Barchiesi F; Scalise G
J Antimicrob Chemother; 1998 Oct; 42(4):445-51. PubMed ID: 9818742
[TBL] [Abstract][Full Text] [Related]
33. Potent antipneumocystis and antitoxoplasma activities of piritrexim, a lipid-soluble antifolate.
Kovacs JA; Allegra CJ; Swan JC; Drake JC; Parrillo JE; Chabner BA; Masur H
Antimicrob Agents Chemother; 1988 Apr; 32(4):430-3. PubMed ID: 2967669
[TBL] [Abstract][Full Text] [Related]
34. A cytotoxicity assay for evaluation of candidate anti-Pneumocystis carinii agents.
Cushion MT; Chen F; Kloepfer N
Antimicrob Agents Chemother; 1997 Feb; 41(2):379-84. PubMed ID: 9021195
[TBL] [Abstract][Full Text] [Related]
35. Pneumocystis carinii f. sp. carinii synthesizes de novo four homologs of ubiquinone.
Sul D; Kaneshiro ES
J Eukaryot Microbiol; 2001; 48(2):182-7. PubMed ID: 12095106
[TBL] [Abstract][Full Text] [Related]
36. A meta-analysis of salvage therapy for Pneumocystis carinii pneumonia.
Smego RA; Nagar S; Maloba B; Popara M
Arch Intern Med; 2001 Jun; 161(12):1529-33. PubMed ID: 11427101
[TBL] [Abstract][Full Text] [Related]
37. Design, synthesis, and antifolate activity of new analogues of piritrexim and other diaminopyrimidine dihydrofolate reductase inhibitors with omega-carboxyalkoxy or omega-carboxy-1-alkynyl substitution in the side chain.
Chan DC; Fu H; Forsch RA; Queener SF; Rosowsky A
J Med Chem; 2005 Jun; 48(13):4420-31. PubMed ID: 15974594
[TBL] [Abstract][Full Text] [Related]
38. New semisynthetic pneumocandins with improved efficacies against Pneumocystis carinii in the rat.
Schmatz DM; Powles MA; McFadden D; Nollstadt K; Bouffard FA; Dropinski JF; Liberator P; Andersen J
Antimicrob Agents Chemother; 1995 Jun; 39(6):1320-3. PubMed ID: 7574523
[TBL] [Abstract][Full Text] [Related]
39. An enzyme-linked immunosorbent assay for enumeration of Pneumocystis carinii in vitro and in vivo.
Durkin MM; Bartlett MS; Queener SF; Shaw MM; Lee CH; Smith JW
J Clin Microbiol; 1992 Dec; 30(12):3258-62. PubMed ID: 1452712
[TBL] [Abstract][Full Text] [Related]
40. 2,4-Diaminothieno[2,3-d]pyrimidine analogues of trimetrexate and piritrexim as potential inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
Rosowsky A; Mota CE; Wright JE; Freisheim JH; Heusner JJ; McCormack JJ; Queener SF
J Med Chem; 1993 Oct; 36(21):3103-12. PubMed ID: 8230096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
